SCH51048在肺曲霉病实验模型中的评估。
Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
作者信息
Allendoerfer R, Loebenberg D, Rinaldi M G, Graybill J R
机构信息
Department of Medicine, University of Texas Health Science Center at San Antonio, USA.
出版信息
Antimicrob Agents Chemother. 1995 Jun;39(6):1345-8. doi: 10.1128/AAC.39.6.1345.
Abstract
The efficacy of a novel triazole, SCH51048, was assessed with a murine model of pulmonary aspergillosis and was compared with those of SCH39304 and itraconazole. A wide range of doses of SCH51048 (5 to 50 mg/kg of body weight) was evaluated. Mortality was significantly delayed in mice treated with doses of 5 mg of SCH51048 per kg or greater in comparison with mortality in controls (P < 0.05). Both SCH51048 and SCH39304 at higher doses (30 and 50 mg/kg) reduced the number of viable Aspergillus fumigatus organisms in lung tissue (P < 0.05). In the present model, itraconazole neither delayed mortality nor significantly reduced the counts in tissue at the doses used. We conclude that SCH51048 is an effective therapy for murine pulmonary aspergillosis.
摘要
利用小鼠肺曲霉病模型评估了新型三唑类药物SCH51048的疗效，并将其与SCH39304和伊曲康唑的疗效进行了比较。评估了SCH51048的多种剂量（5至50毫克/千克体重）。与对照组相比，每千克给予5毫克或更高剂量SCH51048治疗的小鼠死亡率显著延迟（P<0.05）。较高剂量（30和50毫克/千克）的SCH51048和SCH39304均减少了肺组织中烟曲霉活菌数量（P<0.05）。在本模型中，伊曲康唑既未延迟死亡率，在所使用的剂量下也未显著减少组织中的菌数。我们得出结论，SCH51048是治疗小鼠肺曲霉病的有效疗法。
相似文献
1
Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.SCH51048在肺曲霉病实验模型中的评估。
Antimicrob Agents Chemother. 1995 Jun;39(6):1345-8. doi: 10.1128/AAC.39.6.1345.
2
Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.小鼠肺曲霉病：用新型三唑类药物SCH39304进行治疗
Am Rev Respir Dis. 1990 Sep;142(3):512-5. doi: 10.1164/ajrccm/142.3.512.
3
Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis.在两种侵袭性曲霉病小鼠模型中，D0870与伊曲康唑和两性霉素B的疗效比较。
Antimicrob Agents Chemother. 1995 Aug;39(8):1809-14. doi: 10.1128/AAC.39.8.1809.
4
Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.在急性侵袭性肺曲霉病小鼠模型中，伊曲康唑预先暴露会减弱随后两性霉素B治疗的疗效。
Antimicrob Agents Chemother. 2002 Oct;46(10):3208-14. doi: 10.1128/AAC.46.10.3208-3214.2002.
5
Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis.伏立康唑联合两性霉素B或米卡芬净在豚鼠侵袭性肺曲霉病模型中的疗效
Clin Microbiol Infect. 2004 Oct;10(10):925-8. doi: 10.1111/j.1469-0691.2004.00958.x.
6
Efficacy of ambruticin analogs in a murine model of invasive pulmonary aspergillosis.安布罗霉素类似物在侵袭性肺曲霉病小鼠模型中的疗效。
Antimicrob Agents Chemother. 2006 Oct;50(10):3464-6. doi: 10.1128/AAC.00558-06.
7
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.SCH-56592在侵袭性曲霉病的暂时中性粒细胞减少小鼠模型中对一株伊曲康唑敏感和一株伊曲康唑耐药的烟曲霉分离株的疗效。
Antimicrob Agents Chemother. 1997 Jul;41(7):1504-7. doi: 10.1128/AAC.41.7.1504.
8
In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.系统性小鼠曲霉病中烟曲霉对体内伊曲康唑的耐药性。EBGA网络。烟曲霉生物型和基因型欧洲研究小组。
J Med Microbiol. 1999 Dec;48(12):1087-1093. doi: 10.1099/00222615-48-12-1087.
9
In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.实验室筛选出的烟曲霉分离株对两性霉素B的体内耐药性。
Antimicrob Agents Chemother. 2005 Jan;49(1):428-30. doi: 10.1128/AAC.49.1.428-430.2005.
10
Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.SCH56592在兔侵袭性曲霉病模型中的疗效。
Antimicrob Agents Chemother. 2000 Mar;44(3):780-2. doi: 10.1128/AAC.44.3.780-782.2000.
引用本文的文献
1
Antifungal Activity of Leaves of Mangroves Plant Acanthus licifolius Against Aspergillus fumigatus.红树林植物叶状老鼠簕叶片对烟曲霉的抗真菌活性
Indian J Pharm Sci. 2012 Nov;74(6):575-9. doi: 10.4103/0250-474X.110614.
2
Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model.
Pharm Res. 2006 May;23(5):901-11. doi: 10.1007/s11095-006-9904-6. Epub 2006 May 5.
3
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.新型口服三唑类抗真菌药ER-30346在曲霉病、念珠菌病和隐球菌病实验模型中的疗效。
Antimicrob Agents Chemother. 1996 Oct;40(10):2243-7. doi: 10.1128/AAC.40.10.2243.
4
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.新型口服三唑类抗真菌药ER-30346的体外和体内抗真菌活性，其具有广谱抗真菌谱。
Antimicrob Agents Chemother. 1996 Oct;40(10):2237-42. doi: 10.1128/AAC.40.10.2237.
本文引用的文献
1
Invasive aspergillosis. Progress in early diagnosis and treatment.侵袭性曲霉病。早期诊断与治疗的进展。
Am J Med. 1981 Oct;71(4):571-7. doi: 10.1016/0002-9343(81)90208-4.
2
Treatment of experimental murine aspergillosis with BAY n7133.
J Infect Dis. 1983 Nov;148(5):898-906. doi: 10.1093/infdis/148.5.898.
3
Simplified bioassay method for measurement of flucytosine or ketoconazole.测定氟胞嘧啶或酮康唑的简化生物测定方法。
J Clin Microbiol. 1985 Aug;22(2):157-60. doi: 10.1128/jcm.22.2.157-160.1985.
4
Treatment of invasive aspergillosis with itraconazole.伊曲康唑治疗侵袭性曲霉病
Am J Med. 1989 Jun;86(6 Pt 2):791-800. doi: 10.1016/0002-9343(89)90475-0.
5
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.侵袭性曲霉病的抗真菌及手术治疗：2121例已发表病例综述
Rev Infect Dis. 1990 Nov-Dec;12(6):1147-201. doi: 10.1093/clinids/12.6.1147.
6
Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.小鼠肺曲霉病：用新型三唑类药物SCH39304进行治疗
Am Rev Respir Dis. 1990 Sep;142(3):512-5. doi: 10.1164/ajrccm/142.3.512.
7
Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.在浅表和全身性念珠菌病、脑膜隐球菌病及肺曲霉病的啮齿动物模型中对Bay R 3783进行评估。
Antimicrob Agents Chemother. 1990 Mar;34(3):448-54. doi: 10.1128/AAC.34.3.448.
8
Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.SCH 39304治疗实验性侵袭性曲霉病的疗效。
Antimicrob Agents Chemother. 1991 Oct;35(10):1985-8. doi: 10.1128/AAC.35.10.1985.
9
Future directions of antifungal chemotherapy.抗真菌化疗的未来发展方向。
Clin Infect Dis. 1992 Mar;14 Suppl 1:S170-81. doi: 10.1093/clinids/14.supplement_1.s170.
10
Synergistic nephrotoxicity of amphotericin B and cortisone acetate in mice.
J Infect Dis. 1978 Jun;137(6):789-94. doi: 10.1093/infdis/137.6.789.
Zotero 插件